e-ISSN: Pending
Replication FailureOpen accessImmunology and Microbiology· cited by 10

A phase 3, randomized, double-blind, multicenter, placebo-controlled study of S-588410, a five-peptide cancer vaccine as an adjuvant therapy after curative resection in patients with esophageal squamous cell carcinoma

Tomoki Makino; Hiroshi Miyata; Takushi Yasuda; Yuko Kitagawa; Kei Muro; Jae-Hyun Park; Tetsuro Hikichi; Takahiro Hasegawa · 2024 · Esophagus

WASTE classifies this as Replication Failure · AI classification, approximate

A previously reported effect did not replicate here — verify it holds before you build on it.

Abstract

BACKGROUND: S-588410, a cancer peptide vaccine (CPV), comprises five HLA-A*24:02-restricted peptides from five cancer-testis antigens. In a phase 2 study, S-588410 was well-tolerated and exhibited antitumor efficacy in patients with urothelial cancer. Therefore, we aimed to evaluate the efficacy, immune response, and safety of S-588410 in patients with completely resected esophageal squamous cell carcinoma (ESCC). METHODS: This phase 3 study involved patients with HLA-A*24:02-positive and lymph node metastasis-positive ESCC who received neoadjuvant therapy followed by curative resection. After

Abstract by Tomoki Makino; Hiroshi Miyata; Takushi Yasuda; Yuko Kitagawa; Kei Muro; Jae-Hyun Park; Tetsuro Hikichi; Takahiro Hasegawa, Esophagus (2024) — licensed CC BY 4.0.

About to run something similar?

Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.

WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.

Metadata source: OpenAlex · DOI 10.1007/s10388-024-01072-w